Hong Kong AI drug discovery firm Insilico Medicine Cayman TopCois stepping up the quest to harness artificial intelligence to extend human life.
The company, whose stock has doubled since its December market debut, is working with a US partner to develop what they expect to be among the first AI foundation models dedicated to human longevity science. The venture with closely held Human Life Foundation Models Inc. aims to build an AI system that can identify disease risks earlier and accelerate the discovery of therapies.
The push reflects a broader shift in the health care and pharmaceutical sectors, ...
